Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7484073rdf:typepubmed:Citationlld:pubmed
pubmed-article:7484073lifeskim:mentionsumls-concept:C0020094lld:lifeskim
pubmed-article:7484073lifeskim:mentionsumls-concept:C0683325lld:lifeskim
pubmed-article:7484073lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:7484073lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:7484073lifeskim:mentionsumls-concept:C0205453lld:lifeskim
pubmed-article:7484073lifeskim:mentionsumls-concept:C0024853lld:lifeskim
pubmed-article:7484073pubmed:issue3lld:pubmed
pubmed-article:7484073pubmed:dateCreated1995-12-22lld:pubmed
pubmed-article:7484073pubmed:abstractTextMyositis linked to HTLV-1 is unfrequent. Over a period of 8 years, 14 patients with inflammatory myopathy were diagnosed in Martinique. Seven were seropositive for HTLV 1 antibody; the clinical and pathological data of whom are presented herein. Five patients presented with polymyositis, two with dermatomyositis. All seven patients had extra-muscular clinical features including neuropathy (4/7) and myelopathy (6/7), resulting in a quite peculiar clinical picture. Muscle biopsy showed a neurogenic process combined with myositic changes in 3/7 patients. Corticotherapy led to dramatic improvement in only one case, but with no sustained effect. HTLV 1 may be considered the etiological agent of this form of dermato-polymyositis, characterized by a clearly distinctive clinico-pathological picture, and a poor response to corticotherapy. As in the case of tropical spastic paraparesis/HTLV 1 associated myelopathy, careful assessment of non-steroidal therapy is now warranted.lld:pubmed
pubmed-article:7484073pubmed:languageenglld:pubmed
pubmed-article:7484073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7484073pubmed:citationSubsetIMlld:pubmed
pubmed-article:7484073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7484073pubmed:statusMEDLINElld:pubmed
pubmed-article:7484073pubmed:monthSeplld:pubmed
pubmed-article:7484073pubmed:issn0001-6314lld:pubmed
pubmed-article:7484073pubmed:authorpubmed-author:ArfiSSlld:pubmed
pubmed-article:7484073pubmed:authorpubmed-author:BellancaNNlld:pubmed
pubmed-article:7484073pubmed:authorpubmed-author:VernantJ CJClld:pubmed
pubmed-article:7484073pubmed:authorpubmed-author:SmadjaDDlld:pubmed
pubmed-article:7484073pubmed:authorpubmed-author:CabrePPlld:pubmed
pubmed-article:7484073pubmed:issnTypePrintlld:pubmed
pubmed-article:7484073pubmed:volume92lld:pubmed
pubmed-article:7484073pubmed:ownerNLMlld:pubmed
pubmed-article:7484073pubmed:authorsCompleteYlld:pubmed
pubmed-article:7484073pubmed:pagination206-12lld:pubmed
pubmed-article:7484073pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:meshHeadingpubmed-meshheading:7484073-...lld:pubmed
pubmed-article:7484073pubmed:year1995lld:pubmed
pubmed-article:7484073pubmed:articleTitleClinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique.lld:pubmed
pubmed-article:7484073pubmed:affiliationDepartment of Neurology, University Hospital of Fort-de-France, Martinique, French West Indies.lld:pubmed
pubmed-article:7484073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7484073pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:7484073pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7484073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7484073lld:pubmed